ArticleScientific reports2021
Proteomic blood profiling in mild, severe and critical COVID-19 patients.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 99 citations in OpenAlex.
- Assessing the effects of alternative plant-based meatsJournal of nutritional science · 2022Trial
- Computational proteomics to enhance personalized treatment of COVID-19 and Long COVID.Clinical proteomics · 2026Review
- Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar.Frontiers in immunology · 2026Article
- Influenza virus infection drives upregulation of CD84 across a broad range of immune cells.Clinical & translational immunology · 2026Article
- Integrated miR-omics and proteomics reveal the regulatory role of miR in protein networks associated with COVID-19 disease progression.Frontiers in immunology · 2026Article
- Targeted proteomics reveals immune protein patterns in serum from patients with calcific aortic stenosis.iScience · 2025Article
- The Roles of EDA2R in Ageing and Disease.Aging cell · 2025Review
- Plasma Proteomic Profiling Yields a High-Performance Biomarker Panel for Predicting a Poor Prognosis in Patients with COVID-19.Journal of proteome research · 2025Article
- Cerebrospinal fluid protein profiling of inflammatory and neurobiological markers in Lyme neuroborreliosis.Scientific reports · 2025Article
- Nanopores with an Engineered Selective Entropic Gate Detect Proteins at Nanomolar Concentration in Complex Biological Sample.Journal of the American Chemical Society · 2025Article
- Protein profiling in intensive care unit-treated COVID-19 patients identifies biomarkers of residual lung abnormalities.ERJ open research · 2025Article
- Plasma proteomic profiles correlate with organ dysfunction in COVID-19 ARDS.Physiological reports · 2025Article
- Exploration of the plasma proteomic profile of patients at risk of thromboembolic events.Research and practice in thrombosis and haemostasis · 2025Article
- Utility of Protein Markers in COVID-19 Patients.International journal of molecular sciences · 2025Review
- Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications.Theranostics · 2025Review
- Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.Vaccine · 2025Article
- Associations between physical activity and CVD-related metabolomic and proteomic biomarkers.PloS one · 2025Article
- Challenges with measuring tissue factor antigen and activity in human plasma.Blood vessels, thrombosis & hemostasis · 2024Review
- Leukocyte immunoglobulin-like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond.Cancer innovation · 2024Review
- Delineating sex-specific circulating host response signatures associated with COVID-19 severity and mortality.iScience · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
The recent SARS-CoV-2 pandemic manifests itself as a mild respiratory tract infection in most individuals, leading to COVID-19 disease. However, in some infected individuals, this can progress to severe pneumonia and acute respiratory distress syndrome (ARDS), leading to multi-organ failure and death. This study explores the proteomic differences between mild, severe, and critical COVID-19 positive patients to further understand the disease progression, identify proteins associated with disease severity, and identify potential therapeutic targets. Blood protein profiling was performed on 59 COVID-19 mild (n = 26), severe (n = 9) or critical (n = 24) cases and 28 controls using the OLINK inflammation, autoimmune, cardiovascular and neurology panels. Differential expression analysis was performed within and between disease groups to generate nine different analyses. From the 368 proteins measured per individual, more than 75% were observed to be significantly perturbed in COVID-19 cases. Six proteins (IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1) were identified to be associated with disease severity. The results have been made readily available through an interactive web-based application for instant data exploration and visualization, and can be accessed at https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/ . Our results demonstrate that dynamic changes in blood proteins associated with disease severity can potentially be used as early biomarkers to monitor disease severity in COVID-19 and serve as potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.